Stockscreener 앱 받기
102.69
5.53%
5.38
시간 외 거래:
103.00
0.31
+0.30%
전일 마감가:
$97.31
열려 있는:
$97.77
하루 거래량:
5.89M
Relative Volume:
2.65
시가총액:
$20.16B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
23.35
EPS:
4.3988
순현금흐름:
$945.58M
1주 성능:
+7.63%
1개월 성능:
+1.35%
6개월 성능:
+50.42%
1년 성능:
+53.13%
1일 변동 폭
$97.36
$103.45
1주일 범위
$95.48
$103.45
52주 변동 폭
$53.56
$109.28
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
102.69 | 19.10B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer - MyChesCo
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Why Incyte Corporation (ICY) stock stays on buy listsMarket Performance Report & High Conviction Buy Zone Alerts - DonanımHaber
Can Incyte Corporation stock hit analyst price targetsWatch List & Free Weekly Watchlist of Top Performers - DonanımHaber
Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY) - simplywall.st
Incyte Corp EVP Sells Over $5.6 Million in Company Stock - TradingView — Track All Markets
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Yahoo Finance
Incyte to Present at Upcoming Investor Conference - Business Wire
EC approves Incyte’s Minjuvi combo for follicular lymphoma - Pharmaceutical Technology
Incyte wins European approval of Minjuvi in FL - The Pharma Letter
Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma - Nasdaq
Incyte (INCY) Gains EU Approval for Minjuvi in Follicular Lympho - GuruFocus
Incyte (INCY) Gains European Approval for Minjuvi in New Cancer Treatment - GuruFocus
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Minjuvi approved in EU for relapsed follicular lymphoma treatment By Investing.com - Investing.com South Africa
INCYTE wins European approval for Minjuvi cancer treatment - StreetInsider
(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Is Incyte’s 2025 Surge Justified by Cash Flow Outlook and Oncology Pipeline Progress? - simplywall.st
VP Morrissey Files To Sell 54,008 Of Incyte Corp [INCY] - TradingView — Track All Markets
Is Incyte Corp Gaining or Losing Market Support? - Sahm
Shareholder Stamoulis Files To Sell 187,690 Of Incyte Corp [INCY] - TradingView — Track All Markets
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Is Incyte Stock Outperforming the Nasdaq? - Barchart.com
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance - MyChesCo
Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus
Incyte director Hervé Hoppenot retires from board effective immediately By Investing.com - Investing.com Canada
Incyte Corp EVP & Chief Scientific Officer Sells Shares - TradingView — Track All Markets
Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com
Incyte Corp Announces Board Retirement - TradingView — Track All Markets
Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com
Incyte Announces Change to its Board of Directors - Business Wire
WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat
Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat
Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com
Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat
California Public Employees Retirement System Sells 122,593 Shares of Incyte Corporation $INCY - MarketBeat
Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat
Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now
Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360
Incyte (NASDAQ:INCY) Upgraded at Mizuho - MarketBeat
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace
Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance
Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.79%
자본화:
|
볼륨(24시간):